M. Cassier and D. Stoppa-lyonnet, L'opposition contre les brevets de Myriad Genetics et leur invalidation totale ou partielle en Europe. Premiers enseignements, Med/Sci (Paris), vol.21, pp.658-62, 2005.
DOI : 10.1051/medsci/2005216-7658
URL : http://www.erudit.org/fr/revues/ms/2005-v21-n6-7-ms951/011201ar.pdf

R. Eisenberg, The move toward the privatization of biomedical research, The future of biomedical research, pp.121-125, 1997.

M. Cassier and D. Stoppa-lyonnet, Un juge fédéral et le gouvernement des ÉtatsUnis interviennent contre la brevetabilité des gènes, Med Sci (Paris), vol.27, pp.662-668, 2011.
DOI : 10.1051/medsci/201228s204
URL : http://www.medecinesciences.org/articles/medsci/pdf/2012/07/medsci2012282sp11.pdf

J. Sulston and G. Ferry, The common thread. A story of science, politics, ethics and the human genome, 2002.

J. Calvert and P. B. Joly, How did the gene become a chemical compound ? The ontology of the gene and the patenting of DNA, Social Science Information, vol.50, pp.157-77, 2011.

R. Cook-deegan, J. M. Conley, J. P. Evans, and D. Vorhaus, The next controversy in genetic testing: clinical data as trade secrets ?, Eur J Hum Genet, vol.21, pp.585-593, 2013.

G. Van-overwalle, Turning patent swords into shares, Science, vol.330, pp.1630-1631, 2010.

M. Hopkins and . Hoggart, Biomarkers patents for diagnostics. Problem or solution ?, Nat Biotechnol, vol.30, pp.498-500, 2012.

T. Cassier and D. Stoppa-lyonnet,